However, activation of DNA damage checkpoints is unlikely to be the only mechanism through which MTSS1 downregulation confers therapy refractoriness, because reduced MTSS1 levels augmented resistance not only to classical DNA-damaging AML therapeutics, but also to several other approved anti-cancer agents representing various drug classes. The gene discussed is MTSS1; the disease is cancer.